Finance

Lists
Why is 950210 up 2,52%?
Dive Deeper
950210:KRX
Prestige Biopharma Ltd
5 690,00 KRW
+2,52%
(+140,00) 1D
16-окт., 15:30:30 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 950210...
Open
5 370 KRW
High
5 770 KRW
Low
5 370 KRW
Mkt. cap
341,95 млд
Avg. vol.
33,56 миң
Volume
0,00
52-wk high
14 120 KRW
52-wk low
4 945 KRW
EPS
-896 KRW
Shares outstanding
60,10 млн
No. of employees
64
Open
5 370 KRW
High
5 770 KRW
Low
5 370 KRW
Mkt. cap
341,95 млд
Avg. vol.
33,56 миң
Volume
0,00
52-wk high
14 120 KRW
52-wk low
4 945 KRW
EPS
-896 KRW
Shares outstanding
60,10 млн
No. of employees
64
News stories
From web sources and news partners
About Prestige Biopharma Ltd
CEO-
Employees64
Founded2015
Headquarters-
Sector-
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
2,36 млд
7,81 млд
509,20 млн
15,39 млд
Cost of goods sold
2,23 млд
10,17 млд
12,23 млд
17,68 млд
Cost of revenue
2,23 млд
10,17 млд
12,23 млд
17,68 млд
Research and development expenses
-
-
-
42,51 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
24,95 млд
16,79 млд
14,63 млд
-36,73 млд
Operating expense
24,95 млд
16,79 млд
14,63 млд
20,81 млд
Total operating expenses
27,18 млд
26,96 млд
26,86 млд
38,49 млд
Operating income
-24,82 млд
-19,15 млд
-26,35 млд
-23,10 млд
Other non operating income
4,06 млд
-1,38 млд
-3,05 млд
7,24 млд
EBT including unusual items
-20,76 млд
-20,53 млд
-29,40 млд
-52,36 млд
EBT excluding unusual items
-20,76 млд
-20,53 млд
-29,40 млд
-23,56 млд
Income tax expense
-69,96 млн
-17,84 млн
-20,29 млн
-43,51 млн
Effective tax rate
0,34%
0,09%
0,07%
0,08%
Other operating expenses
-
-
-
573,69 млн
Net income
-12,62 млд
-15,37 млд
-20,56 млд
-42,95 млд
Net profit margin
-534,55%
-196,66%
-4 037,83%
-279,14%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
3,62 млд
Interest expense
-
-
-
-6,92 млд
Net interest expenses
-
-
-
-3,31 млд
Depreciation and amortization charges
-
-
-
6,52 млд
EBITDA
-19,37 млд
-13,70 млд
-20,90 млд
-14,91 млд
Gain or loss from assets sale
-
-
-
-6,37 млн
AI content may include mistakes. Learn more
Google колдонмолору